Prognosis and Staging of Multiple Myeloma

San-Miguel, Jesús F.; Gutiérrez, Norma C.

doi:10.1007/978-1-4614-3764-2_32

Neoplastic Diseases of the Blood 2012

DOI: 10.1007/978-1-4614-3764-2_32

|View full text |Cite

Prognosis and Staging of Multiple Myeloma

Jesús F. San-Miguel

Norma C. Gutiérrez

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2013

2019

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 241 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12,13 Myeloma arises from the multifocal proliferation of long-lived PCs and, despite all available therapies, remains invariably fatal. 14,15 Autologous stem-cell transplantation and immunomodulatory agents, for example, lenalidomide and pomalidamide, and the proteasome inhibitor bortezomib have improved clinical management to extend overall survival for selected myeloma patients from o3 to 45 years. 16,17 Although the precise molecular events that generate MM remain incompletely understood, our understanding of events that underlie its development have greatly advanced.…”

mentioning

confidence: 99%

MicroRNA theragnostics for the clinical management of multiple myeloma

et al. 2013

View full text Add to dashboard Cite

Theragnostics represent cutting-edge, multi-disciplinary strategies that combine diagnostics with therapeutics in order to generate personalized therapies that improve patient outcome. In oncology, the approach is aimed at more accurate diagnosis of cancer, optimization of patient selection to identify those most likely to benefit from a specific therapy and to generate effective therapeutics that enhance patient survival. MicroRNAs (miRNAs) are master regulators of the human genome that orchestrate myriad cellular pathways to control growth during physiologic and pathologic conditions. Compelling evidence shows that miRNA deregulation promotes events linked to tumor initiation, metastasis and drug resistance as seen in multiple myeloma (MM), an invariably fatal hematologic malignancy. miRNAs are readily detected in body fluids, for example, serum, plasma, urine, as well as circulating tumor cells to demonstrate their potential as readily accessible, non-invasive diagnostic and prognostic biomarkers and potential therapeutics. Specific miRNAs are aberrantly expressed early in myelomagenesis and may more readily detect high-risk disease than current methods. Although only recently discovered miRNAs have rapidly advanced from preclinical studies to evaluation in human clinical trials. The development of miRNA theragnostics should provide widely applicable tools for the targeted delivery of personalized medicines to improve the outcome of patients with MM.

show abstract

mentioning

confidence: 99%

MicroRNA theragnostics for the clinical management of multiple myeloma

et al. 2013

View full text Add to dashboard Cite

show abstract

Multiple Myeloma: Clinicohaematological Study of 3 Years at a Tertiary Care Centre

Jagtap¹,

Jagtap²,

Boral³

et al. 2019

jebmh

View full text Add to dashboard Cite

BACKGROUNDMultiple myeloma is also called as plasma cell myeloma or myelomatosis. It is a malignant clonal proliferation of neoplastic plasma cells within the bone marrow. Its incidence increases with age. Multiple Myeloma accounts for 1% of all human cancers and 10% of all haematological malignancies. We wanted to study clinical presentation of multiple myeloma and haematological parameters along with bone marrow aspiration with biopsy interpretations. METHODSThis is descriptive, analytical study. The total 212 bone marrow aspirations were done during study period at Department of Pathology and evaluated for MM. The Study period was 3 years from January 2016 to December 2018 at our tertiary care hospital. Detailed clinical data including all biochemical investigations, routine and specific haematological investigations were done. The imaging findings, serum electrophoresis, urine analysis etc were considered. The bone marrow aspiration and biopsy study were done. RESULTSIn data analysis for 3 years, total 12 cases of multiple myeloma were diagnosed. The male: female ratio was 2:1. The age range was 55-79 years, with mean age 67 years. The common clinical presentation was bony pain (66%), followed by renal failure (25%), neurological symptom (pain) (41.7%), easy fatigability (66.7%), infection (6%), etc. On investigation, it was observed that anaemia (75%), lymphocytosis (33.3%), elevated ESR (66.7%), increased serum creatinine (83.3%), increased serum calcium (91.7%), BJ proteinuria (50%) were seen in various cases. On serum electrophoresis, M-band was noted in all patients. Bone marrow plasmacytosis was noted in 100% cases with mean count was 41%. On radio imaging 75% showed bony lytic lesions. CONCLUSIONSElderly patients with unexplained anaemia, bony pain and renal manifestations should be investigated for multiple myeloma. Bone marrow aspiration, electrophoresis, and related investigations. It plays an important role in diagnosis and management of multiple myeloma cases.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Prognosis and Staging of Multiple Myeloma

Cited by 2 publications

References 241 publications

MicroRNA theragnostics for the clinical management of multiple myeloma

MicroRNA theragnostics for the clinical management of multiple myeloma

Multiple Myeloma: Clinicohaematological Study of 3 Years at a Tertiary Care Centre

Contact Info

Product

Resources

About